12:00 AM
 | 
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Palonosetron: Began Phase III testing

Helsinn Healthcare SA, Lugano, Switzerland
Product: Palonosetron
Business: Cancer
Therapeutic category: Receptor antagonist, Adjunct
Target: 5-HT3...

Read the full 56 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >